MiRNA-Based Therapeutics in Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (25 October 2021) | Viewed by 29755
Special Issue Editors
Interests: microRNA; breast cancer; HER2; targeted therapy; prognostic and predictive biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
MicroRNAs (miRNAs) play an active role in the modulation of cellular physiological processes such as apoptosis, cell-cycle control, cell proliferation, DNA repair, and metabolism. Increasing evidence has revealed a deregulation of miRNA levels in cancer and a negative regulation of gene and protein expression by acting as oncogenes or tumor suppressors. Several studies both in vitro and in vivo have demonstrated that correction of miRNAs’ alteration in cancer cells could revert their malignant phenotypes.
This Special Issue focuses on miRNA-based therapeutic strategies for cancer treatment, a topic that has raised extreme interest in the scientific community in recent years. Experimental approaches such as inhibition of oncogenic miRNAs or replacement of tumor suppressors both in vitro and in vivo will be included. New approaches using viral or nonviral agents to achieve miRNA systemic delivery considering safety and potential off-target effects will be discussed.
Dr. Marilena V. Iorio
Dr. Orazio Fortunato
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- microRNA
- Cancer
- Nanoparticle delivery
- microRNA replacement
- microRNA inhibition
Related Special Issue
- RNAi-Based Therapeutics in Pharmaceuticals (12 articles)